A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
← catalyst calendarNCT06940739 · readout ≤ 2,141 d
Sponsored by Iovance Biotherapeutics, Inc. (industry) · IOVA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
42estimated
Sites
5
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-11 | actual | When the study began enrolling |
| Primary completion | Jun 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Unresectable Melanoma
- Metastatic Melanoma
- Ocular Melanoma
Intervention
- Biological: IOV-3001
Primary outcomes
what the primary-completion date above is the date OFSafety and Tolerability
measured Up to 30 days
Recommended Dose for Phase 2
measured Up to 30 days
Permalink · IOVA's whole pipeline · Catalyst calendar · Every registered study · What changed